• POSTER
  Differences in Lopinavir Plasma Concentrations Comparing Kaletra Film Coated Tablets and Soft
  Gelatin Capsules Translate into Distinct Lipid Abnormalities
  J Morello, S Rodriguez-Novoa, F Blanco, et al
  PDF Poster        Abstract
• POSTER
  Bone Mineral Density (BMD) 96 Weeks after Antiretroviral Therapy (ART) Initiation: A Randomized
  Trial Comparing Efavirenz (EFV)-Based Therapy to a Lopinavir/ritonavir (LPV/r)-Containing Regimen
  with Simplification to LPV/r Monotherapy
  TT Brown, GA McComsey ,  M King , et al 
  PDF Poster        Abstract
• A WEEK IN REVIEW FEATURED REPORT
  POSTER
  Study M05-730 Primary Efficacy Results at Week 48: Phase 3, Randomized, Open-Label Study
  of Lopinavir/ritonavir (LPV/r) Tablets Once Daily (QD) versus Twice Daily (BID), Co-Administered
  with Tenofovir DF (TDF) + Emtricitabine (FTC) in Antiretroviral-Naïve (ARV) HIV-1 Infected Subjects
  J Gathe,  BA da Silva,  M Loutfy , et al  
  PDF Poster      Abstract
• POSTER
  Prevalence, Mutational Patterns and Phenotypic Correlates of the L76V Protease
  Mutation in Relation to LPV Associated Mutations
  M Norton , T Young,  N Parkin  et al 
  PDF Poster      Abstract
• POSTER
  Lopinavir/ritonavir (LPV/r) 500/125 mg BID Plus Efavirenz Approximate the Pharmacokinetic
  Exposure of LPV/r 400/100 mg BID Administered Alone in Healthy Adult Subjects
  J Ng , C Klein ,  J Xiong , et al 
  PDF Poster      Abstract
• A WEEK IN REVIEW FEATURED REPORT
  POSTER
  Impact of a 48-week Lopinavir/r Monotherapy on HIV1-DNA in Blood Cells in the MONARK Trial
  V Avettand-Fenoe , P Flandre ,  ML Chaix , et al  
  PDF Poster     Abstract
• Therapeutic Drug Monitoring of Lopinavir and Saquinavir in Thai HIV-infected Children
  J van der Lugt, T Bunupuradah, P Kosalaraska, et al  
  PDF Poster     Abstract
• Lopinavir/Ritonavir (LPV/r) + 2 Nucleoside Analogues as Second-line ART in Protease
  Inhibitor-naïve Adults in South Africa: Outcomes and Adverse Effects
  R Murphy ,  R Sunpath  , A Nijhawan, et al^.
  Abstract
• Increased Lopinavir Concentrations on Once-daily Tablets as Compared with Capsules and
  Liquid Formulations
  B Best ,  G Rieg ,  S Sun,  et al
  Abstract
• Lopinavir Population Pharmacokinetics on HIV-infected Pregnant Women
  M Bouillon Pichault, V Jullien, E Azria, et al
  Abstract
• High-dose Lopinavir and Standard-dose Emtricitabine Pharmacokinetics during Pregnancy
  and Postpartum
  B Best, A Stek, C Hu, et al
  Abstract
• CONFERENCE PDF POSTER
  Lopinavir Pharmacokinetic Maturational Changes and Variability in HIV-infected Infants
  Beginning Kaletra Therapy at <6 Weeks of Age
  E Capparelli, J Pinto, B Robbins, et al
  PDF Poster     Abstract
• Drug Interaction between Antimalarial Drugs and Lopinavir/Ritonavir
  P German, S Parikh, J Lawrence, et al
  Abstract
• Recommended Dose of Lopinavir/Ritonavir is Sub-optimal in Protease Inhibitor-experienced Children
  N Rakhmanina, J Van Den Anke, M Van Guilder,  et al
  Abstract
• Early Postpartum Pharmacokinetics of Lopinavir when Initiated Intrapartum in Thai Women:
  A Substudy of the IMPAACT P1032 Trial
  T Cressey, R Van Dyke G Jourdain, et al
  Abstract
• Effect of Baseline Characteristics on Treatment Outcomes in ACTG 5142: A Prospective,
  Randomized, Phase III Trial of NRTI-, PI-, and NNRTI-sparing Regimens for Initial Treatment
  of HIV-1 Infection
  S Riddler, R Haubrich, G DiRienzo, et al
  Abstract

15th Conference on Retroviruses and Opportunistic Infections
Index of Kaletra Data